Get started
Work

230P Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial

Year: 2023
Type: article
DOI: 10.1016/j.annonc.2023.09.2953
Authors: Y. Loriot, S. Pant, O. Witt, D.A. Reardon, T. Doi, S. Qin, J. Tabernero, G. Iyer, C. Massard, D. Arnold, I. Lugowska, O. Carranza, M. Gutierrez, H. Winter, H. Sweiti, S. Thomas, M. Gormley, J. Zhang, S. Triantos, M.H.H. Schuler
Institutions: Université Paris-Saclay, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, German Cancer Research Center, University Hospital Heidelberg, National Center for Tumor Diseases, Hopp Children's Cancer Center Heidelberg, Harvard University, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, National Cancer Center Hospital East, Nanjing University of Chinese Medicine, Nanjing General Hospital of Nanjing Military Command, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Memorial Sloan Kettering Cancer Center, Inserm, Asklepios Klinik Altona, Asklepios, Asklepios Kliniken Hamburg, The Maria Sklodowska-Curie National Research Institute of Oncology, Hospital Privado de Comunidad, Hackensack University Medical Center, Janssen Research & Development (United States), Essen University Hospital, University of Duisburg-Essen
Language: English
Open Access status: bronze
OpenAlex ID: W4387809747
FWCI:
Cites:
Cited by:
Related to: 10